Cell-Laden Hydrogel as a Clinical-Relevant 3D Model for Analyzing Neuroblastoma Growth, Immunophenotype, and Susceptibility to Therapies.
3D cancer model
B7-H3 and IFN-γ
KIRS/HLA-I
NK cells
PD-Ls
PVR
immunotherapy
neuroblastoma
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2019
2019
Historique:
received:
28
02
2019
accepted:
24
07
2019
entrez:
27
8
2019
pubmed:
27
8
2019
medline:
21
10
2020
Statut:
epublish
Résumé
High risk Neuroblastoma (NB) includes aggressive, metastatic solid tumors of childhood. The survival rate improved only modestly, despite the use of combination therapies including novel immunotherapies based on the antibody-mediated targeting of tumor-associated surface ligands. Treatment failures may be due to the lack of adequate
Identifiants
pubmed: 31447858
doi: 10.3389/fimmu.2019.01876
pmc: PMC6697063
doi:
Substances chimiques
Alginates
0
Antineoplastic Agents
0
Hydrogels
0
Imatinib Mesylate
8A1O1M485B
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1876Références
Science. 1999 Jul 30;285(5428):730-2
pubmed: 10426994
J Exp Med. 1999 Nov 15;190(10):1505-16
pubmed: 10562324
Biomaterials. 2001 May;22(10):1077-84
pubmed: 11352088
J Exp Med. 2003 Aug 18;198(4):557-67
pubmed: 12913096
J Biomech. 2004 Aug;37(8):1263-9
pubmed: 15212932
Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12640-5
pubmed: 15314238
J Cell Biol. 2004 Sep 13;166(6):877-87
pubmed: 15364962
Blood. 2005 Mar 1;105(5):2066-73
pubmed: 15536144
Cancer Res. 2004 Dec 15;64(24):9180-4
pubmed: 15604290
Blood. 2005 Jul 15;106(2):566-71
pubmed: 15784725
Biophys J. 2005 Jul;89(1):635-50
pubmed: 15849239
Biosens Bioelectron. 2006 Feb 15;21(8):1483-92
pubmed: 16084714
Biophys J. 2006 Apr 15;90(8):3012-8
pubmed: 16461391
Cell. 2006 Aug 25;126(4):677-89
pubmed: 16923388
Clin Cancer Res. 2006 Nov 15;12(22):6772-80
pubmed: 17121898
Blood. 2007 Jun 1;109(11):4873-81
pubmed: 17272509
Cancer Res. 2007 Feb 1;67(3):1317-25
pubmed: 17283169
Cancer Res. 2007 Mar 15;67(6):2857-64
pubmed: 17363609
Tissue Eng. 2007 May;13(5):1035-47
pubmed: 17439391
Cancer Cell. 2007 Jun;11(6):539-54
pubmed: 17560335
Int J Oncol. 2008 May;32(5):1011-9
pubmed: 18425327
Histopathology. 2008 Jul;53(1):73-80
pubmed: 18613926
Biophys J. 2008 Nov 1;95(9):4426-38
pubmed: 18658232
J Exp Med. 2008 Dec 22;205(13):2959-64
pubmed: 19029379
J Immunol. 2009 Mar 15;182(6):3530-9
pubmed: 19265131
J Neurooncol. 2010 May;97(3):409-18
pubmed: 19890606
J Immunol. 2010 Jan 15;184(2):902-11
pubmed: 20008292
Int Immunol. 2010 Aug;22(8):651-60
pubmed: 20587542
Biomaterials. 2010 Nov;31(32):8494-506
pubmed: 20709389
Proc Natl Acad Sci U S A. 2010 Dec 14;107(50):21659-64
pubmed: 21118979
Cancer Res. 2011 Feb 1;71(3):716-24
pubmed: 21266363
Trends Immunol. 2011 Aug;32(8):364-72
pubmed: 21752715
Clin Cancer Res. 2012 Jan 1;18(1):105-17
pubmed: 22080438
Cancer Lett. 2012 Jun 1;319(1):23-30
pubmed: 22182450
Clin Cancer Res. 2012 Jul 15;18(14):3834-45
pubmed: 22615450
Tissue Eng Part A. 2013 Mar;19(5-6):669-84
pubmed: 23013450
Nat Rev Immunol. 2013 Feb;13(2):145-9
pubmed: 23348417
Curr Opin Biotechnol. 2013 Oct;24(5):841-6
pubmed: 23545441
Nat Rev Cancer. 2013 Jun;13(6):397-411
pubmed: 23702928
Cancer Lett. 2014 Feb 28;343(2):172-8
pubmed: 24141191
Immunol Lett. 2014 Oct;161(2):168-73
pubmed: 24361820
J Biol Chem. 2014 Mar 7;289(10):6969-77
pubmed: 24451371
Front Immunol. 2014 Feb 12;5:56
pubmed: 24575100
Clin Cancer Res. 2014 Oct 1;20(19):5064-74
pubmed: 24714771
Biotechnol Adv. 2014 Nov 15;32(7):1256-1268
pubmed: 25116894
Cancer Immunol Immunother. 2015 Apr;64(4):409-18
pubmed: 25549845
J Immunol. 2015 May 1;194(9):4518-27
pubmed: 25825444
BMC Cancer. 2015 Apr 10;15:250
pubmed: 25884903
PLoS One. 2015 May 07;10(5):e0125343
pubmed: 25951238
Oncoimmunology. 2015 Mar 2;4(6):e1008824
pubmed: 26155422
PLoS One. 2015 Dec 14;10(12):e0144139
pubmed: 26657086
Oncoimmunology. 2015 Jul 15;5(1):e1064578
pubmed: 26942080
Nat Rev Cancer. 2016 May;16(5):275-87
pubmed: 27079802
J Allergy Clin Immunol. 2017 Jan;139(1):335-346.e3
pubmed: 27372564
Sci Rep. 2016 Aug 03;6:30854
pubmed: 27484403
J Hematol Oncol. 2016 Aug 15;9(1):70
pubmed: 27526682
Sci Rep. 2016 Oct 13;6:35367
pubmed: 27734939
Biomaterials. 2017 Jan;115:141-154
pubmed: 27889665
Onco Targets Ther. 2016 Nov 22;9:7207-7218
pubmed: 27920558
Comput Math Methods Med. 2016;2016:3628124
pubmed: 28044089
Immunol Rev. 2017 Mar;276(1):52-65
pubmed: 28258699
Oncotarget. 2017 May 23;8(21):35088-35102
pubmed: 28456791
J Immunol. 2017 Aug 15;199(4):1516-1525
pubmed: 28701512
MAbs. 2018 Jan;10(1):55-61
pubmed: 29120699
Cancer Res. 2018 Mar 15;78(6):1471-1483
pubmed: 29259008
Acta Biomater. 2018 Apr 1;70:84-97
pubmed: 29447961
Semin Immunopathol. 2018 Jul;40(4):331-341
pubmed: 29789862
Nat Med. 2018 Jun;24(6):739-748
pubmed: 29808007
Cell Mol Immunol. 2019 Jan;16(1):40-52
pubmed: 30275538
Oncoimmunology. 2018 Jul 30;7(9):e1468953
pubmed: 30357053
ACS Appl Mater Interfaces. 2018 Dec 12;10(49):41978-41985
pubmed: 30479135
Clin Cancer Res. 2019 Apr 15;25(8):2560-2574
pubmed: 30655315
Cancer Cell. 2019 Feb 11;35(2):221-237.e8
pubmed: 30753824
Polymers (Basel). 2018 Apr 01;10(4):null
pubmed: 30966415
Immunity. 1996 Jun;4(6):573-81
pubmed: 8673704
Int J Cancer. 1996 Oct 21;69(5):403-7
pubmed: 8900375
J Exp Med. 1998 Jun 15;187(12):2065-72
pubmed: 9625766
J Exp Med. 1998 Sep 7;188(5):953-60
pubmed: 9730896